Department of Obstetrics and Gynecology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, Institute for Healthcare Delivery Science, NewYork, New York, USA.
Clin Infect Dis. 2024 Mar 20;78(3):681-689. doi: 10.1093/cid/ciad614.
Detection and treatment of anal histologic high-grade squamous intraepithelial lesions (hHSIL) prevents anal cancer. However, anal hHSIL incidence among women with human immunodeficiency virus (HIV, WHIV) remains unknown. Performance of anal high-risk human papillomavirus ([hr]HPV), anal cytology (anal-cyt), and both for hHSIL detection longitudinally over 2 years also remains undetermined.
We determined 2-year incidence and cumulative risk estimates (2-y-CR) of anal hHSIL among WHIV using prevalence and incidence (per 100 person-years [py]) observations stratified by baseline hrHPV and/or anal-cyt results.
In total, 229 WHIV with complete baseline data were included in the analysis; 114 women without prevalent anal hHSIL were followed with 2 annual evaluations. Median age was 51, 63% were Black, and 23% were Hispanic. Anal hrHPV or abnormal anal-cyt was associated with an increased risk of incident anal hHSIL at 2 years (18.9/100py [95% confidence interval {CI} 11.4-31.3] and 13.4/100py [95% CI 8.0-22.7], respectively) compared with no detection of anal HPV or negative cytology (2.8/100py [95% CI 1.1-7.4] and 4.2 [95% CI, 1.8-10.2]) The presence of anal hrHPV with abnormal cytology was associated with 2-y-CR of anal hHSIL of 65.6% (95% CI 55.4%-75%); negative hrHPV with negative cytology was associated with 2-y-CR of anal hHSIL of 9.2% (95% CI 7.0-16.0).
Detection of anal hrHPV or abnormal anal cytology are comparable predictors for 2-y-CR of anal hHSIL. The absence of anal hrHPV combined with negative cytology was predictive of a lower (but measurable) risk of developing anal hHSIL. These findings provide important data to inform anal cancer screening guidelines for WHIV.
检测和治疗肛门组织学高级别鳞状上皮内病变(hHSIL)可预防肛门癌。然而,人类免疫缺陷病毒(HIV,WHIV)女性中肛门 hHSIL 的发病率尚不清楚。肛门高危型人乳头瘤病毒([hr]HPV)、肛门细胞学(anal-cyt)以及这两者在 2 年内对 hHSIL 的检测性能也尚未确定。
我们通过基线 hrHPV 和/或 anal-cyt 结果分层,确定了 WHIV 中在 2 年内发生肛门 hHSIL 的发病率和累计风险估计值(2-y-CR)。
共有 229 名具有完整基线数据的 WHIV 纳入了分析;114 名无既往肛门 hHSIL 的女性进行了 2 次年度评估。中位年龄为 51 岁,63%为黑人,23%为西班牙裔。肛门 hrHPV 或异常 anal-cyt 与 2 年内发生肛门 hHSIL 的风险增加相关(18.9/100py [95%CI 11.4-31.3] 和 13.4/100py [95%CI 8.0-22.7]),而未检测到肛门 HPV 或细胞学阴性则与风险较低相关(2.8/100py [95%CI 1.1-7.4] 和 4.2 [95%CI,1.8-10.2])。存在肛门 hrHPV 伴异常细胞学与肛门 hHSIL 的 2-y-CR 为 65.6%(95%CI 55.4%-75%);hrHPV 阴性伴细胞学阴性与肛门 hHSIL 的 2-y-CR 为 9.2%(95%CI 7.0-16.0)。
检测肛门 hrHPV 或异常 anal-cyt 是预测肛门 hHSIL 2-y-CR 的可比指标。肛门 hrHPV 阴性伴细胞学阴性提示发生肛门 hHSIL 的风险较低(但可测量)。这些发现为 WHIV 的肛门癌筛查指南提供了重要数据。